Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Lead exposure testing failures land Bendigo lab $10K fine
The laboratory pleaded guilty to failing to arrange for biological monitoring of two workers...
AI and deep-tech research program receives $400K grant
A program designed to help scientists transform AI and deep-tech research into commercially...
Australia–Vietnam collaborative research projects — applications open
Until 20 July, grant applications for projects in recycling and waste management, a sustainable...
